Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial

Affiliations

• ¹ Hypertrophic Cardiomyopathy Center, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA; Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA; Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: desaim2@ccf.org.
• ² Division of Cardiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
• ³ Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA; Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
• ⁴ Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
• ⁵ Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
• ⁶ Department of Cardiology, Duke University, Durham, North Carolina, USA.
• ⁷ Department of Cardiology, New York University, New York, New York, USA.
• ⁸ Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
• ⁹ Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
• ¹⁰ Department of Cardiology, Corewell Health, Grand Rapids, Michigan, USA.
• ¹¹ Department of Cardiology, Westchester Medical Center, Valhalla, New York, USA.
• ¹² Hypertrophic Cardiomyopathy Center, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA; Department of Cardiothoracic Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
• ¹³ Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA.
• ¹⁴ Bristol Myers Squibb, Princeton, New Jersey, USA.
• ¹⁵ University of Missouri-Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.